BB-Cl-Amidine hydrochloride
| 中文名称 | BB-Cl-Amidine hydrochloride |
|---|---|
| 中文同义词 | 化合物 T10482L |
| 英文名称 | BB-Cl-Amidine hydrochloride |
| 英文同义词 | BB-Cl-Amidine hydrochloride |
| CAS号 | |
| 分子式 | C??H??Cl?N?O |
| 分子量 | 0 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | Mol File |
| 结构式 |
BB-Cl-Amidine hydrochloride 性质
BB-Cl-Amidine hydrochloride 是肽基精氨酸脱胺酶 (PAD) 的抑制剂。
PAD.
Treatment with BB-Cl-amidine subtly reduces splenomegaly in MRL/lpr mice, while there is a trend towards increased circulating levels of anti-NET antibodies with PAD inhibitor treatment. However, neither PAD inhibitor affected body weight or total IgG levels. Indeed, treatment with both Cl-amidine and BB-Cl-amidine significantly improves endothelium-dependent vasorelaxation. The BB-Cl-amidine group also shows a strong trend towards downregulation of IRGs. Treatment with either Cl-amidine or BB-Cl-amidine significantly improves muzzle alopecia, in many cases preventing it entirely.
| Animal Model: | MRL/lpr mice. |
| Dosage: | 1 mg/kg. |
| Administration: | Subcutaneous injection daily from 8 to 14 weeks of age. |
| Result: | Significantly improved endothelium-dependent vasorelaxation and showed a strong trend towards downregulation of IRGs. |